Quadrimeningo Injection

babies: quadrimeningo is safe for babies. human studies have shown no side effects to the baby.
lactating mother: quadrimeningo is safe if prescribed by your doctor. human studies have shown inadequate evidence of side effects to the developing baby.
pregnancy: safe if prescribed by your doctor. human studies have shown inadequate evidence of risk to the baby.
driving: quadrimeningo is safe during driving. it does not affect the ability to drive.
alcohol: consult your doctor. no studies have shown evidence whether it is safe to consume alcohol while taking the quadrimeningo.
kidney: consult your doctor. human studies have shown inadequate evidence in patients with kidney disease.
liver: safe if prescribed by your doctor. human studies have shown inadequate evidence in patients with liver disease.
.

headche fever irritation pain at injection site.

the quadrimeningo is a vaccine that helps to develop immunity by initiating a mild infection. this type of infection does not cause illness but stimulates the production of antibodies to protect against infections..

if vaccine dose is missed, inform your doctor and arrange another visit as soon as possible. .

• quadrimeningo is given by injection into the muscle of the upper arm. • this vaccine may cause shivering, headache, fever or malaise.
• take adequate rest after getting a vaccination. • avoid close contact with infected people.
.

contraindicated • quadrimeningo + adalimubab: concurrent use leads to an increased risk of infection. • quadrimeningo + budesonide: concurrent use leads to an increased risk of infection.
• quadrimeningo + prednisolone: concurrent use leads to an increase in infection. serious • quadrimeningo + mercaptopurine: concurrent use decreases quadrimeningo levels by increasing mercaptopurine.
• quadrimeningo + brodalumab: concurrent use leads to the risk of infection. monitor closely • quadrimeningo + cyclosporine: concurrent use leads to a decrease in quadrimeningo levels by increasing cyclosporine.
• quadrimeningo + ibrutinib: concurrent use leads to the risk of infection. minor • quadrimeningo + chloroquine: concurrent use decreases quadrimeningo levels by increasing chloroquine.
• quadrimeningo + ozanimod: concurrent use leads to a decrease in quadrimeningo levels by an increase in ozanimod. .